

HBP SURGERY WEEK 2023

MARCH 23 THU - 25 SAT, 2023 | BEXCO, BUSAN, KOREA www.khbps.org

& The 58th Annual Congress of the Korean Association of HBP Surgery





ABST-0397

Clinical Utility Of A Cancer Genome Panel Test For Patients With Hepato-biliary-pancreatic Cancer

Yu SAWADA*¹, Ryusei MATSUYAMA¹, Tomoaki TAKAHASHI¹, Kentaro MIYAKE¹, Yasuhiro YABUSHITA¹, Yuki HOMMA¹, Shingo KATO², Itaru ENDO¹

¹Department Of Gastroenterological Surgery, Yokohama City University Graduate School Of Medicine, JAPAN ²Department Of Cancer Genome Diagnosis, Yokohama City University Graduate School Of Medicine, JAPAN **Background**: To search for therapeutic drug candidates, our hospital has operated MSK-IMPACT and FoundationOne as a cancer genome panel (CGP) test.

Methods: We examined genetic analysis for 114 cases of hepato-biliary-pancreatic cancer using a CGP test from 2016 to 2022.

Results: One hundred eight patients could be analyzed, including 3 patients with liver cancer, 46 patients with biliary tract cancer, and 59 patients with pancreatic malignant tumor. Of 3 patients with liver cancer, no patients were treated with the candidate drug. Of 46 patients with biliary tract cancer, 22 patients (48%) had gene mutations, which can be expected to have therapeutic drug candidates with effect in evidence level of a clinical trial, and 5 patients (11%) were treated with the candidate drug. Seven of 22 biliary tract cancer patients with therapeutic drug candidates had already died or not treated due to cancer progression at the time of explanation of the results. Of 59 patients with pancreatic malignant tumor, 8 patients (14%) had gene mutations, which can be expected to have therapeutic drug candidates, and 1 patient (1.7%) was treated with the candidate drug.

Conclusions: The CGP test for biliary tract cancer can identify genetic mutations that can be therapeutic targets in about half of cases, suggesting clinical usefulness. Even if a candidate drug is identified, treatment may become difficult due to the cancer progression. It is necessary to provide information of CGP test early so that the timing of treatment is not missed.

Corresponding Author: Yu SAWADA (t116036e@yokohama-cu.ac.jp)